Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Abstract Neurodegeneration entails progressive loss of neuronal structure as well as function leading to cognitive failure, apathy, anxiety, irregular body movements, mood swing and ageing. Proteomic dysregulation is considered the key factor for neurodegeneration. Mechanisms involving deregulated processing of proteins such as amyloid beta (Aβ) oligomerization; tau hyperphosphorylation, prion misfolding; α-synuclein accumulation/lewy body formation, chaperone deregulation, acetylcholine depletion, adenosine 2A (A2A) receptor hyperactivation, secretase deregulation, leucine-rich repeat kinase 2 (LRRK2) mutation and mitochondrial proteinopathies have deeper implications in neurodegenerative disorders. Better understanding of such pathological mechanisms is pivotal for exploring crucial drug targets. Herein, we provide a comprehensive outlook about the diverse proteomic irregularities in Alzheimer’s, Parkinson’s and Creutzfeldt Jakob disease (CJD). We explicate the role of key neuroproteomic drug targets notably Aβ, tau, alpha synuclein, prions, secretases, acetylcholinesterase (AchE), LRRK2, molecular chaperones, A2A receptors, muscarinic acetylcholine receptors (mAchR), N-methyl-D-aspartate receptor (NMDAR), glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) and mitochondrial/oxidative stress-related proteins for combating neurodegeneration and associated cognitive and motor impairment. Cross talk between amyloidopathy, synucleinopathy, tauopathy and several other proteinopathies pinpoints the need to develop safe therapeutics with ability to strike multiple targets in the aetiology of the neurodegenerative disorders. Therapeutics like microtubule stabilisers, chaperones, kinase inhibitors, anti-aggregation agents and antibodies could serve promising regimens for treating neurodegeneration. However, drugs should be target specific, safe and able to penetrate blood–brain barrier..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Cellular and molecular neurobiology - 40(2019), 3 vom: 04. Okt., Seite 313-345 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dar, Khalid Bashir [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Chaperones |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2019 |
|---|
| doi: |
10.1007/s10571-019-00741-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2057090922 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2057090922 | ||
| 003 | DE-627 | ||
| 005 | 20230511104333.0 | ||
| 007 | tu | ||
| 008 | 200819s2019 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10571-019-00741-0 |2 doi | |
| 035 | |a (DE-627)OLC2057090922 | ||
| 035 | |a (DE-He213)s10571-019-00741-0-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 610 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 100 | 1 | |a Dar, Khalid Bashir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2019 | ||
| 520 | |a Abstract Neurodegeneration entails progressive loss of neuronal structure as well as function leading to cognitive failure, apathy, anxiety, irregular body movements, mood swing and ageing. Proteomic dysregulation is considered the key factor for neurodegeneration. Mechanisms involving deregulated processing of proteins such as amyloid beta (Aβ) oligomerization; tau hyperphosphorylation, prion misfolding; α-synuclein accumulation/lewy body formation, chaperone deregulation, acetylcholine depletion, adenosine 2A (A2A) receptor hyperactivation, secretase deregulation, leucine-rich repeat kinase 2 (LRRK2) mutation and mitochondrial proteinopathies have deeper implications in neurodegenerative disorders. Better understanding of such pathological mechanisms is pivotal for exploring crucial drug targets. Herein, we provide a comprehensive outlook about the diverse proteomic irregularities in Alzheimer’s, Parkinson’s and Creutzfeldt Jakob disease (CJD). We explicate the role of key neuroproteomic drug targets notably Aβ, tau, alpha synuclein, prions, secretases, acetylcholinesterase (AchE), LRRK2, molecular chaperones, A2A receptors, muscarinic acetylcholine receptors (mAchR), N-methyl-D-aspartate receptor (NMDAR), glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) and mitochondrial/oxidative stress-related proteins for combating neurodegeneration and associated cognitive and motor impairment. Cross talk between amyloidopathy, synucleinopathy, tauopathy and several other proteinopathies pinpoints the need to develop safe therapeutics with ability to strike multiple targets in the aetiology of the neurodegenerative disorders. Therapeutics like microtubule stabilisers, chaperones, kinase inhibitors, anti-aggregation agents and antibodies could serve promising regimens for treating neurodegeneration. However, drugs should be target specific, safe and able to penetrate blood–brain barrier. | ||
| 650 | 4 | |a Chaperones | |
| 650 | 4 | |a Drug targets | |
| 650 | 4 | |a Neurodegeneration | |
| 650 | 4 | |a Mitophagy | |
| 650 | 4 | |a Free radicals | |
| 700 | 1 | |a Bhat, Aashiq Hussain |4 aut | |
| 700 | 1 | |a Amin, Shajrul |4 aut | |
| 700 | 1 | |a Reshi, Bilal Ahmad |4 aut | |
| 700 | 1 | |a Zargar, Mohammad Afzal |4 aut | |
| 700 | 1 | |a Masood, Akbar |4 aut | |
| 700 | 1 | |a Ganie, Showkat Ahmad |0 (orcid)0000-0001-6295-4959 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular and molecular neurobiology |d Springer US, 1981 |g 40(2019), 3 vom: 04. Okt., Seite 313-345 |w (DE-627)166718858 |w (DE-600)283404-2 |w (DE-576)01517218X |x 0272-4340 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2019 |g number:3 |g day:04 |g month:10 |g pages:313-345 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10571-019-00741-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2019 |e 3 |b 04 |c 10 |h 313-345 | ||